Neurolief

09/09/2025

We are thrilled to share the exciting news that the MOOD study has been published in the esteemed journal of Brain Stimulation.

As the world begins to recognize the immense benefits of Proliv™Rx, let us take a moment to celebrate this milestone and the collective contributions that made it possible.

We are ready to make a difference in treating depression.

Read the full release:

/PRNewswire/ -- Neurolief, a neurotechnology company, is proud to announce the publication of the MOOD study. This trial is the first pivotal multicenter...

08/21/2025

Neurolief is poised to transform the future of depression treatment. Today, we announced a strategic investment from BrainsWay as we prepare for the commercial launch of our groundbreaking at‑home neuromodulation device, Proliv™Rx, designed to tackle Major Depressive Disorder (MDD).

We are now focusing on securing FDA premarket approval and gearing up for Proliv™Rx’s commercial rollout. This partnership paves the way for a new era in mental health care - transforming treatment accessibility and outcomes.

Thank you to everyone joining us on this journey toward more effective, accessible mental health solutions. Stay tuned for updates!

⸻



Read the full release here:

/PRNewswire/ -- Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, today announced a strategic...

07/14/2025

Did you know migraine costs the U.S. more than $36 billion every year? Between doctor visits, ER trips, and expensive meds, it all adds up fast.

But there’s hope. Relivion® MG is a new wearable device that treats migraine without drugs. In studies, it helped people cut their migraine days by nearly two-thirds and reduced how much medicine they needed.

That means fewer headaches, less time lost, and potentially big savings on medical bills.

Curious how it works and why it might change migraine care? Check out the full story here:

A Closer Look at Cost Savings and Healthcare Economics Migraine isn’t just a headache—it’s a multi-billion dollar drain on healthcare systems and economies worldwide. In the U.S. alone, migraine costs are estimated at over $36 billion annually (1), driven by direct medical expenses, lost produ...

07/08/2025

Did you know migraine affects more than 40 million people in the U.S.?

It’s not just a headache. It’s a serious neurological condition that can disrupt daily life. The good news is that new treatments and devices are changing how people manage migraine, offering hope for better relief and fewer side effects than traditional medications.

We’ve just shared a new blog post that explains how big the migraine problem really is in the U.S., and what’s happening in the world of treatment options. If you or someone you love lives with migraine, this is worth a read.

Check it out here:

How Big Is the Migraine Market in the United States? If you’ve ever had a migraine, you know it’s not just a bad headache. It’s a full-body shutdown—pounding pain, nausea, light and sound sensitivity, sometimes even vision loss. It can wreck your whole day, if not your whole week. And if you...

04/07/2025

Neurolief Unveils Groundbreaking MOOD Study Results at International Brain Stimulation Meeting

See the full poster here: https://lnkd.in/g6qJ-zYT

03/12/2025

Neurolief, a leader in brain stimulation for mental health and neurological disorders, is pleased to announce the appointment of Owen Scott Muir, M.D., DFAACAP, as its fractional Chief Medical Officer (CMO).

Dr. Muir brings a unique combination of expertise in psychiatry and extensive experience with FDA-regulated medical devices. His leadership will play a pivotal role in advancing Neurolief’s mission to deliver safe and effective brain stimulation therapy for patients with major depressive disorder who have not responded to traditional treatments.

Dr. Muir is a dual board-certified psychiatrist in both child and general psychiatry, with expertise in managing complex mood disorders. He serves as a Clinical Assistant Professor of Medicine at the Menninger Department of Psychiatry and Behavioral Sciences, where he contributes to advancing psychiatric education and research.

As the co-founder of Fermata, a neuromodulation-first medical practice, Dr. Muir has been at the forefront of integrating innovative technologies with clinical practice, driving meaningful improvements in patient outcomes. A prolific scientific author and speaker, he has also served as strategic advisor to industry.

10/15/2024

We may be a bit late to World Mental Health Day (October 10th), but the truth is, it’s never too late to start prioritizing your mental well-being.

Migraines can take a toll not just on your physical health, but on your mental health too. Chronic pain, anxiety, and the emotional strain of dealing with migraines can feel overwhelming—but there are ways to manage both.

At Neurolief, we believe in treating the whole person. Our non-invasive wearable Relivion MG device not only provides migraine relief but may also help reduce the stress and anxiety that often come with chronic pain. 🤕✨

Let’s remind ourselves that each day is a new opportunity to care for our mental health, whether through therapy, stress management, or innovative treatments like neuromodulation.

🧠 Your mental health journey is ongoing, and we’re here to support you every step of the way. 💪

10/08/2024

We recently unveiled our pivotal multicenter RCT clinical study results for our upcoming Proliv™Rx brain neuromodulation therapy at the prestigious 7th Annual Neuropsychiatric Drug Summit in Boston.

"Proliv™Rx offers an accessible and effective solution for patients whose depression is unresponsive to medications, many of whom have endured years of persistent symptoms. This therapy has the potential to become an essential tool in the mental health treatment landscape."

- Dr. Linda Carpenter, Professor of Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University

/PRNewswire/ -- Neurolief, a leading pioneer in neuromodulation technology, recently unveiled its pivotal multicenter RCT clinical study results for its...

06/25/2024

Neurolief Announces Breakthrough Results from Pivotal Clinical Trial of Brain Neuromodulation System for Treating Major Depressive Disorder. This study marks a historic milestone as the first ever Randomized Controlled Trial (RCT) to demonstrate success in a non-pharmacological home therapy for Treatment Resistant Major Depression.
Read the full Press Release here: https://www.prnewswire.com/news-releases/neurolief-announces-breakthrough-results-from-pivotal-clinical-trial-of-brain-neuromodulation-system-for-treating-major-depressive-disorder-302181896.html?tc=eml_cleartime

04/26/2024

Meet Kaylon Evans, a warrior who found relief with Relivion MG.

His testimonial is a beacon of hope for those battling migraine disease. Now, with Relivion more accessible and affordable than ever, relief is within reach.

Learn more at Relivion.com

01/02/2024

Living with migraine can be hard, but it feels much lighter when we have the understanding and support from our support system. Share this with someone you love that is living alongside migraine.

Let them know that you see them.
Let them know that you understand that it is hard.
Let them know that you recognize how disabling migraine can be.

Follow for more migraine support.

—

Relivion is a non-invasive, drug-free, clinically proven, FDA-cleared therapy for the treatment of migraine. Relivion is the only FDA-cleared neuromodulation device on the market that stimulates both the trigeminal AND occipital nerves, responsible for migraine pain. Click the link in bio to learn more about Relivion therapy and learn how to try our 90-day trial.

12/22/2023

5 Mindful Mindset Shifts for Migraine:

💫 Healing is not linear, healing takes time. It can take time to respond to a migraine treatment or to find a treatment that helps improve the frequency and severity of attacks.
💫 Joy and pain can coexist.
💫 Life is about being not doing.
💫 There is beauty and connection to be found
in little moments.
💫 This is temporary, this will pass (for severe
migraine attacks)

—-

Follow for more relatable migraine content & support and click the link in bio to learn more about Relivion MG, a clinically proven, noninvasive, drug-free way to treat migraine attacks.